… New molecular targeted drugs and their combination with cytotoxic anticancer agents are …
EGFR mutation-positive lung cancer and the strategies aimed at overcoming drug resistance; …

Multiple mutations in the EGFR gene are a major cause for the failure of Erlotinib and Gefitinib
in the treatment of patients harboring non-small-cell lung cancer (NSCLC) who initially …

… EGFR mutation, arising in cis with the germline EGFR … a germline EGFR T790M 'drug–resistance'
mutation associated … we note that characteristic EGFR activating mutations, both in this …

… Intratumor Heterogeneity Intratumor heterogeneity may also account for drug resistance [64];
for example, activating EGFR mutations and MET amplification were shown to coexist in a …

… that T790M mutants retain low-nanomolar affinity for gefitinib. Furthermore, we show that
the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases …

… resistance is the outgrowth of tumor cells with additional TKI-resistant EGFR mutations. Here
… common EGFR TKI resistance mutation, T790M. We treated mice bearing tumors harboring …

… ErbB2 with the EGFR mutation library and selected for drug-resistant growth in the presence
… by which the various mutations confer drug resistance are speculative predictions based …

… Consequently, it is critical to establish mechanisms by which drug resistance occurs and to
… -sensitive EGFR mutation. The most important and frequent drug-resistant EGFR mutations …

… ”—isogenic pairs of drug-sensitive and drug-resistant EGFR mutant lung cancer cells—and …
acquisition of drug resistance in vitro. Importantly, the study of these EGFR mutant cells has …

… In this review, we discuss the mechanisms of EGFR-TKIs drug resistance and the clinical
strategies to overcome drug resistance from the perspective of EGFR-TKIs combined treatment. …